

RECEIVED
CENTRAL FAX CENTER

OCT 12 2006

Attorney Dkt. No. M233 1030.1

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-42 (Cancelled)

43. (Original) A pharmaceutical formulation for oral administration of insulin comprising a particulate pharmaceutical substrate having an application of an insulin coating, wherein the particulate pharmaceutical substrate is free of a polysaccharide.

44. (Original) The oral pharmaceutical formulation of claim 43, wherein the insulin coating includes a material selected from the group consisting of coating agents, controlled release agents, sustained release agents, pharmaceutical excipient agents, and combinations thereof.

45. (Original) The oral pharmaceutical formulation of claim 44, wherein the agent is selected from the group consisting of colorants, film-forming polymers, plasticizers, surfactants, permeation enhancers, buffering agents, dispersions of ethyl cellulose, coating lacquers, pigments, and combinations thereof.

46. (Original) The oral pharmaceutical formulation of claim 43, wherein the insulin comprises an insulin load on the substrate ranging from about 0.1% to about 30% weight/weight.

47. (Original) The oral pharmaceutical formulation of claim 43, wherein the substrate is selected from the group consisting of a calcium material, cellulose, and combinations thereof.

48. (Original) The oral pharmaceutical formulation of claim 47, wherein the calcium material is selected from the group consisting of calcium carbonate, calcium citrate, dibasic

Attorney Dkt. No. M233 1030.1

calcium phosphate dihydrate, monobasic calcium phosphate, tribasic calcium phosphate, anhydrous dibasic calcium phosphate, and combinations thereof.

49. (Original) The oral pharmaceutical formulation of claim 43, further including another coating.

50. (Original) The oral pharmaceutical formulation of claim 49, wherein another coating is under the insulin coating, over the insulin coating, or a combination thereof.

51. (Original) The oral pharmaceutical formulation of claim 49, wherein the other coating comprises a material selected from the group consisting of coating agents, controlled release agents, sustained release agents, pharmaceutical excipient agents, and combinations thereof.

52. (Original) The oral pharmaceutical formulation of claim 51, wherein the agent is selected from the group consisting of colorants, film-forming polymers, plasticizers, surfactants, permeation enhancers, buffering agents, dispersions of ethyl cellulose, coating lacquers, pigments, and combinations thereof.

53. (Original) The oral pharmaceutical formulation of claim 43, wherein the particulate pharmaceutical substrate having an application of an insulin coating is encapsulated in a gelatin capsule or is compressed into a tablet.

Claim 54 (Cancelled).

55. (Original) An oral pharmaceutical formulation of insulin comprising a particulate dibasic calcium phosphate dihydrate pharmaceutical substrate having an application of an insulin coating, wherein: (a) the insulin is present in a load on the substrate ranging from about 0.1% to

Attorney Dkt. No. M233 1030.1

30% weight/weight, and (b) the substrate is free of a polysaccharide and has been coated with a permeation enhancer.

56. (New) The oral pharmaceutical formulation of Claim 1, wherein the insulin is hexyl insulin monoconjugate-2 polydisperse.

57. (New) The oral pharmaceutical formulation of Claim 55, wherein the insulin is hexyl insulin monoconjugate-2 polydisperse.